Cyclacel Pharmaceuticals to Present New Clinical Data at 2024 ASCO Annual Meeting Highlighting Fadraciclib’s Potential as a Precision Medicine for Cancer
Title:
A phase 1 study evaluating the safety, pharmacokinetics, and efficacy of fadraciclib, an oral CDK2/9 inhibitor, in patients with advanced solid tumors and lymphoma
Abstract No. for Publication:
3125
Session Title:
Poster Session – Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
